Siplizumab (CD2/LFA-2) Antibody, Monoclonal
Code | Size | Price |
---|
PSI-10-088-0.1mg | 0.1mg | £657.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Isotype: IgG1-kappa
Antibody Clonality: Recombinant Antibody
Regulatory Status: RUO
Shipping:
blue ice
Storage:
Store at -80˚C
Images
Documents
Further Information
Additional Names:
MEDI-507, CD2/LFA-2, CD2/LFA-2
Background:
Siplizumab has been shown to cause depletion of T-cells.It is therefore considered to be an immunomodulator in clinical settings where the depletion of T-cells may have clinical benefits,such as certain autoimmune diseases and T-cell cancers.In addition, preclinical studies have also suggested that siplizumab,by binding to the CD2 receptor,may selectively produce cell death and reduce cancerous cells.
Buffer:
PBS buffer pH7.5
Concentration:
batch dependent
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
Humanized / CD2/LFA-2 [Homo sapiens]
NCBI Organism:
homo sapiens
Purification:
>95%
Research Area:
Drug Analogues
Source:
CHO cells
Swissprot #:
P06729,Q53F96
User NOte:
Optimal dilutions for each application to be determined by the researcher.